What is MLTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.95B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MLTX?

P/E (TTM) is n/a and 52-week range is $8.90 to $23.29 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MLTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MLTX?

The company profile lists net income (TTM) near -$326M, EPS (TTM) near -$3.83 when available from the market-data feed. Figures are informational and may lag live markets.

Where is MoonLake Immunotherapeutics based, and what identifiers does Chartloom list?

The company context section lists headquarters in Zug, Zug, CH, 85.1M shares outstanding, ISIN KY61559X1045 when available from company profile and filing metadata.

MoonLake Immunotherapeutics

$MLTX

Health Care · Biotechnology

IR Run Scenarios

Browse other companiesFree AI scores and summaries for more stocks

MoonLake Immunotherapeutics

$MLTX

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 130 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Employees

130

Website

moonlaketx.com/

IPO

2020-10-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

KY61559X1045

Headquarters

Zug, Zug, CH

Shares outstanding

85.1M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

87.60%

Browse other companiesFree AI scores and summaries for more stocks

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 130 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Employees

130

Website

moonlaketx.com/

IPO

2020-10-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)